A Study to Determine if South African Medical by Van Niekerk, Diederik Johannes
 - 1 - 
 
 
 
 
 
A Study to Determine if South African Medical 
Practitioners in Urban Areas Follow the Southern African 
Hypertension Society Guideline for the Treatment and 
Management of Uncomplicated Hypertension 
 
 
 
 
 
Diederik Johannes van Niekerk 
 
0107750D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A research report submitted to the Faculty of Health Sciences, University of the 
Witwatersrand, in part fulfillment of the requirements for the degree 
of 
M.Sc.(Med) (Pharmaceutical Affairs) 
 
 
 
Johannesburg 2005 
 
 - 2 - 
DECLARATION 
 
I, Diederik Johannes Van Niekerk, declare that this research report is my own work. It 
is being submitted for examination (re-examination) in part fulfilment for the degree 
of Master of Science in Medicine (Pharmaceutical Affairs) at the University of the 
Witwatersrand, Johannesburg. It has not been submitted before for any degree at this 
or any other University. 
 
 
Signed by: 
 
 
 
__________________________________ 
DIEDERIK JOHANNES VAN NIEKERK (ID: 760106 5123 083) 
 
 
 
 
On this ……… day of ……………………………., 2005 
 
 
 
 
 
 
 
 
SIGNATURE OF SUPERVISOR 
 
 
Signed by: 
 
 
 
____________________ 
PROF. A. WOODIWISS 
 
 
 
 
On this ……. day of ………………………………, 2005 
 
 
 
 
 
 
 
 
 - 3 - 
DEDICATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vir Oupa – Ons mis jou: 
 
Diederik Johannes Van Niekerk 
 
1912-2001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 4 - 
ABSTRACT 
 
The prescription habits of general practitioners are continually under the scrutiny of 
ethical critics. There are numerous factors that influence a practitioner’s decision as to 
which antihypertensive agents to prescribe for the treatment of hypertension. As 
outlined in various international and national guidelines for the management of 
hypertension, the recommended treatment depends on ethnicity, current life-style, 
diet, smoking, age, gender, family history and possible underlying or secondary 
conditions such as diabetes mellitus, heart failure, isolated systolic hypertension, 
myocardial infarction, pregnancy, and evidence of coronary artery disease (CAD), 
stroke or peripheral vascular disease.  
 
Currently the control of blood pressure in patients with hypertension is far from 
optimal with over 70% of hypertensive patients being reported as having imperfect 
control. A number of factors related to the patient, the practitioner or the medication 
may explain the high incidence of inadequate blood pressure control. One possible 
explanation for the poor control of blood pressure may be that practitioners fail to 
comply with the guidelines.  
 
Hence the aim of my study was firstly to determine whether a practitioner’s decision 
as to which medication to prescribe in the treatment of hypertension is influenced by 
the Southern African Hypertension Society Guidelines. Secondly, in an attempt to 
assess the validity of the results of the primary analysis, the actual prescription habits 
(MediCross® database) were assessed and compared to the general practitioner’s 
recall of their prescription habits. 
 
Questionnaires were distributed to 320 MediCross® practitioners and prescription 
habits were identified and substantiated by the screening of an existing MediCross® 
database. I chose as my sample MediCross® general practitioners, as they are 
demographically representative of all major urban areas in South Africa; likely to be 
open-minded to supporting research and answering questionnaires (as MediCross® is 
part of a Clinical Research Site Management Organisation); and I had access to the 
database of the prescriptions made by MediCross® practitioners hence enabling me to 
fulfil my second objective. However, it must be kept in mind that these practitioners 
are representative of general practitioners in urban areas only (as the title of my 
research report indicates).  
 
My results show that 33.1% adhere to the guidelines (when a non-conservative 
definition of diuretics is used); 27% have heard of the guidelines and have a copy of 
them. When asked to give their own opinion however, 39% thought they adhered to 
the guidelines. The results also show that ACE inhibitors are the most commonly 
prescribed drug class for uncomplicated hypertension but a comparison to a 
MediCross® database, of which the quality is questionable, does not support this. 
 
As the response rate to the questionnaires was only 24.7%, these results are only a 
pilot study; however they suggest that few general practitioners use the guidelines or 
even have a copy of the guidelines. This pilot study suggests that the guidelines need 
to be distributed more widely. Furthermore the general practitioners that responded to 
the questionnaire indicated that the management of hypertension is difficult in that 
there is no single treatment regimen appropriate for all populations and each different 
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patient. It was also their view that clinical guidelines for the management of 
hypertension should more accurately reflect the uncertainty of when to initiate 
treatment and individual variation if they are going to take these guidelines seriously 
and comply with them. 
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1. INTRODUCTION 
 
Hypertension is a chronic disease which affects a large percentage (25%) of the adult 
population worldwide [1,2]. In order to decrease the risk of cardiovascular mortality, 
it is imperative to reduce blood pressure to normal levels (<140/90 mm Hg for 
uncomplicated cases of hypertension) in these subjects [3]. Indeed a progressive 
decrease in cardiovascular mortality in North America, Western Europe, Japan and 
Australasia has been observed in the second half of the twentieth century [4]. This 
reduction in mortality has largely been attributed to the considerable improvement in 
the control of hypertension in these regions during this time period. The Health 
Examination Surveys in the United States have demonstrated that whereas 10% of 
hypertensive subjects had their blood pressure lowered to below 140/90 mmHg in 
1976 – 1980, by 1988 – 1991 this proportion had risen to 27% [5]. However, it is 
important to note that this still leaves over 70% of hypertensive subjects with 
imperfect control (or no treatment at all), as has been reported in many countries [6]. 
Moreover, there are worrying signs that the rate of improvement previously reported 
has now plateaued or even reversed in some cases. In the United Kingdom, a recent 
survey indicated that only 6% of hypertensive patients had their blood pressure 
lowered to 140/90 mmHg [3]. Related to these values indicating poor blood pressure 
control in a large proportion of patients with hypertension, is recent evidence in the 
United States of America that age-adjusted stroke mortality rates have increased 
slightly and that the rate of decline in coronary heart disease (CHD) mortality has now 
decreased.  
 
Even more worrying is the rapid development of the ‘second wave’ epidemic of 
cardiovascular disease that is now flowing through developing countries and the 
former socialist republics. It is evident that death and disability from CHD and 
cerebrovascular disease are increasing so rapidly in these parts of the world that they 
will rank no. 1 and no. 4, respectively, as causes of the global burden of disease by the 
year 2020 [7]. Given the central role of elevated blood pressure in the pathogenesis of 
both CHD and stroke, it is clear that one of the biggest challenges facing public health 
authorities and medical practitioners is the control of hypertension worldwide, both in 
individual patients and at the population level. 
 
The 1998 “WHO – International Society of Hypertension Guidelines for the 
Management of Hypertension” were written to guide specialist physicians responsible 
for the care of patients with high blood pressure. These guidelines are complemented 
by a companion set of Practice Guidelines for general practitioners and other 
clinicians caring for patients with hypertension in various regions around the world, 
including South Africa. The 1999 Guidelines concentrated on the management of 
patients with ‘mild’ hypertension, since there is often uncertainty among clinicians 
and policy makers about how to manage this condition. Since the determinants of 
cardiovascular disease in hypertensive patients are substantially multifactorial, these 
Guidelines provide recommendations for risk reduction through blood pressure 
lowering, in a context that recognizes the importance of strategies for the management 
of other risk factors that commonly affect individuals with hypertension. 
 
It is well established that in Western populations, stroke, CHD and other common 
cardiovascular diseases, such as heart failure, have multiple determinants. The main 
established predictors of these diseases are discussed below. How well these factors 
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predict cardiovascular disease in non-Western populations is less certain, although 
recent evidence from eastern Asian populations suggests that for blood pressure and 
blood cholesterol there may be similar associations in the East and in the West [8]. 
There is very little direct evidence about the determinants of common cardiovascular 
diseases in other large populations such as those of sub-Saharan Africa, India or South 
America. Furthermore, available medications and their costs differ from country to 
country. Hence, it is important that guidelines are tailored for each country. Hence, 
the Southern African Hypertension Society published the Southern African 
Hypertension Society Guideline in 2001. This guideline is based on the guidelines set 
out by the major international health care organizations and societies such as the 
World Health Organisation – International Society for Hypertension, the Joint 
National Committee VI (JNC VI) and the British Hypertension Society. Furthermore, 
the Southern African Hypertension Society Guideline is endorsed by the South 
African Medical Association Guideline Committee. Note that subsequent to me 
embarking on my research project the South African Guidelines have been revised 
and the revisions published (SAMJ March 2004 vol 94, number 3). For my research 
project I focused on the guidelines published in 2001 [15].  
 
Hypertension is a major health challenge in South Africa. The Southern African 
Hypertension Society Guideline is targeted at all healthcare professionals in both the 
public and private health sectors. It reflects realistic objectives that can be applied 
widely and aims to diminish the impact of hypertension in this country. The control of 
hypertension in conjunction with other major risk factors such as cigarette smoking, 
dyslipidaemia and diabetes mellitus, constitutes the ideal approach to the primary 
prevention of artherosclerotic disease, and remains a major challenge for the 
community at large. 
 
As a major contributor to cardiovascular disease (CVD), hypertension is very costly. 
In 1991, CVD accounted for R4-5 billion in direct and indirect costs [9], which was 
7.5% of the direct healthcare spending in South Africa [10]. The Southern African 
Hypertension Society Guideline adopts the approach of a formal estimation of 
cardiovascular risk which will allow for the treatment of those South Africans at 
highest risk and those who can maximally gain from lifestyle and drug interventions 
at the lowest cost, given South Africa’s limited resources. 
 
The first guideline for the management of hypertension at primary healthcare level 
was issued by the Southern African Hypertension Society in 1995 [15]. The current 
document is modeled on recent national [12] and international [13] recommendations, 
particularly those that are strongly evidence-based [14], and emphasizes the trend 
toward risk stratification and the tighter control of blood pressure (BP) once 
management has been started.  
 
Factors that influence blood pressure control are the treating general practitioner, drug 
therapy, patient lifestyle including diet, smoking, alcohol use, physical activity, 
ethnicity, socio-economic status, as well as underlying and related diseases [15]. 
These factors are all addressed in the Southern African Hypertension Society 
Guidelines. However, whether these guidelines are adopted and adhered to by general 
practitioners largely influences blood pressure control. Despite the importance of the 
role of the general practitioner in implementing the guidelines there is a paucity of 
research in South Africa. Results of a small study involving only 15 doctors and 10 
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nurses in the Western Cape suggested that the guidelines were consulted infrequently 
[16]. Various themes including involvement of doctors in the development of the 
guidelines; time constraints; health system problems; conflict with local practices; and 
patient beliefs were identified as barriers to implementation [16]. However the results 
of this small study conducted in the Western Cape may not reflect the attitudes of 
general practitioners from other regions of South Africa. Hence further studies are 
required. 
 
Questions which need to be addressed include: “Are guidelines at all relevant when 
deciding on the treatment of a patient?” “Why do we need guidelines?” “Do general 
practitioners understand the concept of guidelines versus regulations?” “What really 
influences a general practitioner when he prescribes medication for the treatment of a 
disease, in this case uncomplicated hypertension?” These are just some of the 
questions on which this research report aims to shed some objective clarity.  
 
Due to the fact that drug therapy is one of the most easily measured parameters in the 
Southern African Hypertension Society Treatment Guidelines, and the data on drug 
prescription habits of MediCross® was available for research purposes, this research 
project focused on only the drug therapy of hypertension. The guidelines suggest the 
following step wise approach to drug therapy (see Figure 1 below). 
 
As a step towards answering the question of why BP is not controlled in such a large 
proportion of patients, the aim of this research study was to determine if South 
African general practitioners comply with the Southern African Hypertension Society 
Guideline, as published by the Southern African Hypertension Society and endorsed 
by the South African Medical Association Guideline Committee. The extent to which 
a general practitioner’s prescription habits may have been influenced by the Council 
for Medical Schemes algorithm and the prescribed minimum benefits offered to 
medical aid members was beyond the scope of this research report and hence was not 
addressed.  
 
The primary objective of this research study was to determine if South African 
MediCross® general practitioners, that practice in urban areas are managing and 
treating patients with hypertension according to the Southern African Hypertension 
Society Guideline Step Wise Approach. 
 
In an attempt to compare and assess the validity of the results of the primary analysis, 
the MediCross® prescription database was analysed to determine which drugs are 
most commonly prescribed for uncomplicated hypertension. Hence, my secondary 
objective was to identify the drug treatments (trade names) that are most commonly 
prescribed for the treatment of uncomplicated hypertension in MediCross® Clinics. 
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Figure 1: Southern African Hypertension Guidelines Hypertension Treatment 
Algorithm [17]. 
 
 
 
 
 
     NO 
 
Begin or continue 
lifestyle modification 
 
BP>140/90mmHg? 
STEP 1: INITIAL DRUG 
CHOICE 
- Start with low dose of a 
long acting once daily 
drug 
- Titrate dose at 2 
monthly intervals 
GO TO STEP 2 IF ANY 
OF THE FOLLOWING 
ARE PRESENT 
STEP 2: 
- not at goal BP after 
2 months OR 
- troublesome side 
effects 
GO TO STEP 3 IF NOT 
AT GOAL BP AFTER 2 
MONTHS 
NOT AT GOAL BP AFTER 2 
MONTHS, REFRACTORY 
HYPERTENSION, REFER 
APPROPRIATELY 
YES 
Note: there are lower 
BP goals for patients 
with 
- diabetes 
mellitus 
- cardiac failure 
- renal disease 
UNCOMPLICATED 
HYPERTENSION 
Low dose thiazide diuretic 
12.5 to 25 mg hydrochlorothiazide 
OR
COMPELLING INDICATION FOR SPECIFIC 
CLASS EXISTS 
- diabetes mellitus with proteinuria: 
ACE inhibitor 
- evidence of stroke/CHD/PVD: ACE 
inhibitor 
- heart failure: diuretics and ACE 
inhibitors 
- isolated systolic hypertension: 
thiazide/long acting calcium channel 
blocker  
- myocardial infarction: beta 
blockers/ACE inhibitors 
- pregnancy: methyldopa 
STEP 2 DRUG THERAPY 
ADD low dose diuretic or one of 
the following: 
- reserpine (<0.1 mg daily) 
- beta-blocker 
- ACE inhibitor 
- long acting ca channel 
blocker 
- fixed dose combination 
STEP 3 THERAPY
- add another 
drug from step 
2 therapy OR 
- hydralazine OR 
- alpha blocker 
DO NOT USE MORE 
THAN ONE DRUG FROM 
THE SAME CLASS 
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2. METHODOLOGY 
 
Before commencement of the research study, the research proposal was submitted to 
the WITS Human Research Ethics Committee (HREC) for approval. The research 
study only commenced after favourable approval was obtained (Appendix I). Parallel 
to the Ethics Committee application, a submission was also made to the University of 
the Witwatersrand Post Graduate Committee for the conduct of this research study. 
The University Post Graduate Committee approved the proposal unconditionally 
(Appendix II). 
 
2.1 Population 
 
For the purposes of this research study, a population of general practitioners were 
needed that represented the ‘average’ general practitioners as most South Africans 
know them. The population of general practitioners had to be demographically 
representative of all major urban areas in South Africa and they had to be familiar and 
open to research and research questionnaires. MediCross®, with it’s 49 clinics in 
towns and cities across South Africa (see appendix map – Appendix VII), and more 
than 300 general practitioners that practise free and independently, is the only private 
group that could offer such a large population that fit the above-mentioned criteria. 
With MediCross® being part of a Clinical Research Site Management Organisation, 
all MediCross® general practitioners have been introduced to research and are more 
open minded to supporting research and answering questionnaires. Furthermore, 
access was granted to data used for the purposes of the secondary objective of this 
research project and thus it would make scientific sense to try and investigate the 
same population as was used for the primary objective.    
 
Data on the prescription habits of general practitioners, practising within the 
MediCross® Group across South Africa, were gathered with a questionnaire designed 
for the purpose of this research study (Appendix III). For this purpose, all of the 
general practitioners currently practising in the MediCross® Group across South 
Africa, were contacted, either via telephone or via telefax, and asked to complete the 
attached questionnaire. 
 
As at 31 July 2003, there were 49 MediCross® Clinics across South Africa (Appendix 
V). Approximately 320 general practitioners from all 49 clinics were asked to 
complete the questionnaire. They were contacted telephonically or via telefax. A list 
with the names, addresses, telephone numbers, fax numbers and the general 
practitioners practising at each of the MediCross® Clinics, was obtained from Mr. 
Pieter Dorfling, a director of the MediCross® Group (Appendix V). He was informed 
of the intentions to contact all of the general practitioners and interview them. He 
made it clear that the general practitioners only have agreements with MediCross® 
and that they were not MediCross® employees, thus they are free to participate or not, 
whichever they were to choose. Mr. Dorfling was also informed of the intention to use 
data generated in the MediCross® Clinics for the secondary analysis. Rights to this 
data were sold to Hurricane Consulting®. 
 
Mr. Van Zyl Kruger from Hurricane Consulting® was approached during the design 
of this research protocol and he agreed to share the data for the purposes mentioned 
above (secondary objective). Data provided by Hurricane Consulting®, were gathered 
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in the period from 01 November 2000 to 31 December 2003 by a data capturer at each 
MediCross® Clinic. Data captured included demographics, diseases treated and 
medications prescribed, all stratified by clinic. The database is totally anonymous (no 
patient or doctor identifiers) and is being managed and updated by Hurricane 
Consulting® for MediCross® as a marketing tool for the conduct of the feasibility of 
clinical trials in the MediCross® Clinics. With this database, MediCross® can easily 
inform potential clinical trial clients if they have patients that qualify for trials and 
what the geographical distribution of these patients are. 
 
2.2 Primary Objective 
 
The primary objective of this research study was to determine if South African 
general practitioners, that practice in urban areas are managing and treating patients 
with hypertension according to the Southern African Hypertension Society Guideline 
Step Wise Approach. 
 
Interviewing of general practitioners, for purposes of the primary objective, 
commenced in August 2003. Initially, general practitioners were phoned and 
interviewed telephonically, but it was soon discovered that general practitioners were 
not interested in taking calls for this purpose. Furthermore, interviewing of more than 
300 general practitioners telephonically, would take much longer than expected, due 
to the availability constraints of the general practitioners. Subsequently it was decided 
to send the one page questionnaire via fax to all 320 general practitioners with a cover 
page inviting them to participate in an anonymous questionnaire. They were asked to 
complete the questionnaire honestly and a return fax number was provided. By 
December 2003 all 320 general practitioners were contacted and a total of 81 general 
practitioners responded, either by agreeing to answer the questionnaire telephonically 
or by completing the faxed questionnaire and sending it back via fax.  
 
In order to facilitate responder rate and make it easier to answer a simple 
questionnaire was constructed with only 12 questions. For ease of answering the 
general practitioners were requested to supply tradenames of medications.  
 
 
2.3 Secondary Objective 
 
The secondary objective was to identify the drug treatments (trade names) that are 
most commonly prescribed for the treatment of uncomplicated hypertension in 
MediCross® Clinics. 
 
To answer the secondary objective, which was to determine which drugs were most 
frequently prescribed for the treatment of uncomplicated hypertension in the time 
period that the data was gathered (01 November 2000 to 31 December 2003), the 
MediCross®  data base was used . 
 
2.4 Data Analysis and Statistics 
 
Once all the questionnaires had been completed and gathered, questionnaires were 
assigned identification numbers (1-81). Data from the 81 respondents were captured 
in a Microsoft Excel spreadsheet. Once captured, the Excel spreadsheet was validated 
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100%. Medications listed in question 2, 3 and 12 were post-coded using the South 
African Medicines Formulary (SAMF) coding system. [36]  
 
Because of the geographical distribution of MediCross® clinics in South Africa 
(Appendix VII), an assumption was made that the MediCross® medical practitioners 
are representative of medical practitioners in South Africa that practice in urban areas.  
 
The null hypothesis (Ho) is defined as: medical practitioners in South Africa follow 
the Southern African Hypertension Society Guideline in the prescription of 
hypertensive drug treatments for patients suffering from uncomplicated hypertension. 
 
The alternate hypothesis (Ha) is defined as: medical practitioners in South Africa do 
not follow the Southern African Hypertension Society Guideline in the prescription of 
hypertensive drug treatments for patients suffering from uncomplicated hypertension. 
 
Data analysis and graphic presentation of data were performed using SAS® version 
8.2. (analysis) and MS Excel® (data capturing, coding and graphs). 
 
2.4.1 For the Primary Objective: 
Data gathered from the questionnaires were analysed as follows: frequency tables 
were drawn up for each categorical question, in order to look at the data in a 
descriptive manner. Coding was performed (using the SAMF coding system), on data 
gathered from questions 2, 3 and 12, once all the questionnaires were completed and 
data entered into Excel®.  
 
To evaluate the primary objective, data were analysed in the following way:  
 
• For all questionnaires with “YES” answered in Q1 (i.e. Yes, I treat 
Hypertensive patients), a frequency table was drawn up for all Q2 answers and 
for all Q3 answers separately (i.e. the general practitioner is prescribing the 
correct medication); Q2 and Q3 evaluated how compliant the general 
practitioner was to the SAHS Hypertension Treatment Guidelines. 
• A comparative analysis was performed for the 2x1 table frequencies of Q2 and 
Q3 separately, in order to evaluate whether there was a statistical significant 
difference between the reported compliance percentage of the general 
practitioner to the SAHS Hypertension Treatment Guidelines compared to 
100% compliance, as specified by these guidelines. The comparison between 
these percentages (or proportions) was performed using the following methods 
(H0: p1 = p2 and HA: p1≠ p2): 
 
1. A 95% confidence interval (CI) was calculated for the reported “YES” 
proportion and a 95% CI for the 100% proportion – if these CI’s 
overlapped, there was no statistical difference between these 2 
proportions; 
2. A 95% CI was calculated for the difference between the 2 proportions 
as specified in (1) above – if 0 was included in the interval, then there 
is no statistical significant difference between these 2 proportions; 
3. Additionally, a Z-statistic was used, to evaluate whether there was a 
statistical significant difference between these 2 proportions. 
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A p-value of 0.05 was considered to be statistically significant; all statistical tests 
were 2-tailed; 95% confidence intervals were calculated, where applicable.   
 
It is important to note the following:  
 
1. For the purposes of the above calculations, the ideal of 100% 
compliance should be used. However the Z-statistic calculation is not 
possible with a value of 100%. Hence a value as close to 100% as 
possible was used in each case. In other words an ideal percentage 
based on one value smaller than (<) the total was used (e.g. 99.2% for 
Q2 and 99.3% for Q3). 
 
2. The primary objective contain data of 81 respondents and is regarded 
pilot in nature, since no formal sample size calculation was performed. 
 
The evaluation of Q7 was used to cross-check whether the general practitioner was 
actually compliant with the guidelines, from his/her point of view. 
 
Q1 determined the population of general practitioners that treated patients with 
uncomplicated hypertension. As mentioned above, Q2 and Q3 evaluated how 
compliant the general practitioner was to the SAHS Hypertension Treatment 
Guidelines. Q12 provided a calculated estimate of which drug general practitioners 
thought they most frequently prescribed for uncontrolled hypertension. This was used 
for a comparison with results from the secondary analysis. An investigation into the 
possible problems and helpful suggestions were made by looking at the results of Q4, 
5, 6, 8, 9, 10, 11 and 13. 
 
2.4.2 For the Secondary Objective: 
Data from the MediCross® Database, as described above, were investigated and all 
hypertensive drug classes with their frequencies listed, in order to determine which 
drugs were most frequently prescribed for hypertension (regardless of whether 
hypertension was complicated or uncomplicated). 
 
Data were presented graphically, using histograms. 
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3. RESULTS 
 
Eighty one (81) MediCross® general practitioners/ radiologists out of a possible 320 
names responded. Seventy nine (79) were general practitioners and 2 were 
radiologists, hence giving a response rate of 24.7%.  
 
As the questionnaires were completed anonymously I do not have demographic data 
(gender, race) of the general practitioners that responded. However from the facsimile 
numbers it was apparent that they were fairly wide spread across urban areas of South  
Africa. 
 
3.1 Results of the Primary Analysis: 
 
In response to the question “Do you treat patients with uncomplicated hypertension?” 
97.5% of the doctor’s said (yes) they did treat patients with uncomplicated 
hypertension. 
 
Table 1: Do you treat patients with uncomplicated hypertension? 
 Number of observations (n) Percentage of total (%) 
Yes 79 97.5 
No 2 2.5 
Total 81 100.0 
 
In response to the question “What drug treatment do you prescribe as, first line 
treatment for patients with uncomplicated hypertension?”, more doctors (18.5%) 
prescribed ACE inhibitors, with diuretics (13.8%) and indapamide (13.1%) being the 
next most popular drugs, respectively. 
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Figure 2: "What drug treatment do you prescribe as first line treatment for patients with 
uncomplicated hypertension?" Irbesartan/diuretic
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In order to determine whether doctors adhered to the guidelines for the prescribing of 
first-line drug therapy, two definitions of adherence were used. The more 
conservative definition allowed for no interpretation of the guidelines for first line 
treatment and literally only allowed for hydrochlorothiazide and potassium (low-dose 
thiazide diuretic). The less conservative definition allowed for more than one 
interpretation of first-line treatment and allowed for “thiazide-like” diuretics, 
hydrochlorothiazide and potassium, indapamide, bumetanide and other potassium-
sparing agents. Table 2 below shows the medication prescribed as first line therapy 
and whether they adhere to the guidelines according to these two definitions. 
 
Table 2: “What drug treatment do you prescribe as first line treatment for patients 
with uncomplicated hypertention?”  
Drug 
treatment 
code 
Drug treatment name Number of 
observations 
(n) 
Adherent (Yes/No) 
according to more 
conservative 
definition 
Adherent (Yes/No) 
according to less 
conservative 
definition 
C02AA02 Reserpine 1 No No 
C02DA Thiazide derivatives 2 No No 
C03 Diuretics 18 No Yes 
C03AB03 Hydrochlorothiazide + 
potassium 
1 Yes Yes 
C03BA11 Indapamide 17 No Yes 
C03CA02 Bumetanide 1 No Yes 
C03DB Other potassium-sparing 
agents 
6 No Yes 
C07A Beta-blocking agents 9 No No 
C07AB03 Atenolol 1 No No 
C07AB07 Bisoprolol 2 No No 
C07AG02 Carvedilol 1 No No 
C07B Beta-blocking agents and 
diuretics 
4 No No 
C07BB07 Bisoprolol/thiazide 10 No No 
C09A ACE inhibitors 24 No No 
C09AA02 Enalapril 3 No No 
C09AA03 Lisinopril 5 No No 
C09AA04 Perindopril 7 No No 
C09AA05 Ramipril 2 No No 
C09AA06 Quinapril 1 No No 
C09BA ACE inhibitors and 
diuretics 
2 No No 
C09BA03 Lisinopril/diuretic 1 No No 
C09BA08 Cilazapril/diuretic 1 No No 
C09C Angiotensin II 
antagonists 
3 No No 
C09CA03 Valsartan 1 No No 
C09CA04 Irbesartan 1 No No 
C09CA06 Candesartan 3 No No 
C09CA07 Telmisartan 1 No No 
C09DA03 Valsartan/diuretic 1 No No 
C09DA04 Irbesartan/diuretic 1 No No 
Total  130 *   
* Note: This value is greater than (>) the total number of 79 who responded to Q2 
because more than 1 drug treatment, per general practitioner, was indicated in certain 
cases; all drug treatments were included in the analysis 
 
 - 21 - 
a) Adherence using the more conservative definition (first line treatment) 
 
Proportion adherent: p1 = 1/130 = 0.8% compared to ideal p2 = 129/130 = 99.2% 
 
i) 95% confidence interval (95% CI) for p1 and p2 individually: 
95% CI for p1 = 0.8% = [0.0; 2.27%];  
95% CI for p2 = 99.2% = [97.73; 100.00%] 
 
Since these two 95% CI’s do not overlap, there is a statistical significant 
difference between these 2 proportions: p2 is significantly larger than p1. 
 
ii) 95% CI for difference between p1 and p2: 
95% CI for p2-p1 = [96.34; 100.00%] 
 
Since 0 is not included in this 95% CI, one can conclude that there is a statistical 
significant difference between these 2 proportions: p2 is significantly larger than 
p1. 
 
iii) Hypothesis test: Z-statistic = 15.88; p-value = < 0.0001 
 
This hypothesis test concludes that there is a significant statistical difference 
between the 2 proportions compared, namely: 1/130 = 0.8% versus 129/130 = 
99.2%: p2 is significantly larger than p1 (a p-value < 0.05 is regarded as being 
statistically significant). 
 
b) Adherence using the less conservative definition (first line treatment) 
 
Proportion adherent: p1 = 43/130 = 33.1% compared to p2 = 129/130 = 99.2% 
 
i) 95% confidence interval (95% CI) for p1 and p2 individually: 
95% CI for p1 = 33.1% = [24.99; 41.16%];  
95% CI for p2 = 99.2% = [97.73; 100.00%] 
 
Since these two 95% CI’s do not overlap, there is a statistical significant 
difference between these 2 proportions: p2 is significantly larger than p1. 
 
ii) 95% CI for difference between p1 and p2: 
95% CI for p2-p1 = [57.93; 74.38%] 
 
Since 0 is not included in this 95% CI, one can conclude that there is a statistical 
significant difference between these 2 proportions: p2 is significantly larger than 
p1. 
 
iii) Hypothesis test: Z-statistic = 11.27; p-value = < 0.0001 
 
This hypothesis test concludes that there is a significant statistical difference 
between the 2 proportions compared, namely: 43/130 = 33.1% versus 129/130 = 
99.2%: p2 is significantly larger than p1 (a p-value < 0.05 is regarded as being 
statistically significant). 
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In response to the question “What drug treatment do you prescribe as second line 
treatment for patients with uncomplicated hypertension?” most general practitioners 
(13.2%) prescribed ACE inhibitors, with diuretics (10.3%) and calcium-channel 
blockers (9.6%) being the next most popular drugs respectively. 
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Figure 3: "What drug treatment do you prescribe as second line 
treatment for patients with uncomplicated hypertension?"
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In order to determine whether doctors adhered to the guidelines for the prescribing of 
second-line drug therapy, the two definitions of adherence were used again. The more 
conservative definition allowed for the more conservative interpretation in first-line 
prescribing and no subsequent interpretation of the guidelines for second line 
treatment, in other words only drugs that are listed in the step-wise approach in the 
guidelines. This literally only allowed for low-ceiling diuretics (thiazides), 
hydrochlorothiazide and potassium (low-dose thiazide diuretic), reserpine, beta-
blocking agents, ACE-inhibitors, and long acting calcium channel blockers. The less 
conservative definition, again, allowed for more than one interpretation of second-line 
treatment and hence allowed for any diuretics, hydrochlorothiazide and potassium 
(thiazide diuretic), reserpine, beta-blocking agents, ACE-inhibitors, any calcium 
channel blockers or any fixed dose combinations. Table 3 below shows the 
medication prescribed as second line therapy and whether they adhere to the 
guidelines according to these two definitions. 
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Table 3: “What drug treatment do you prescribe as second line treatment for patients 
with uncomplicated hypertention?”  
Drug treatment 
code 
Drug treatment name Number of 
observations 
(n) 
Adherent (Yes/No) 
according to more 
conservative 
definition 
Adherent (Yes/No) 
according to less 
conservative 
definition 
C02AC05 Moxonidine 1 No No 
C02CA Alpha-adrenoreceptor 
antagonists 
6 No No 
C03 Diuretics 14 No Yes 
C03A Low-ceiling diuretics, 
thiazides 
2 Yes Yes 
C03AA03 Hydrochlorothiazide 1 Yes Yes 
C03BA11 Indapamide 5 Yes Yes 
C03DB Other potassium-sparing 
agents 
1 No Yes 
C07A Beta-blocking agents 11 Yes Yes 
C07AB03 Atenolol 4 Yes Yes 
C07AB07 Bisoprolol 4 Yes Yes 
C07AG02 Carvedilol 2 Yes Yes 
C07B Beta-blocking agents 
and diuretics 
1 Yes Yes 
C07BB07 Bisoprolol/thiazide 10 Yes Yes 
C07CB03 Atenolol/diuretic 1 Yes Yes 
C08 Calcium-channel 
blockers 
13 Yes Yes 
C08CA01 Amlodipine 3 Yes Yes 
C08CA02 Felodipine 2 Yes Yes 
C08CA05 Nifedipine 1 Yes Yes 
C08DA01 Verapamil 1 Yes Yes 
C09A ACE inhibitors 18 No No 
C09AA02 Enalapril 9 Yes Yes 
C09AA03 Lisinopril 5 Yes Yes 
C09AA04 Perindopril 6 Yes Yes 
C09BA04 Perindopril/diuretic 2 No No 
C09C Angiotensin II 
antagonists 
6 No No 
C09CA01 Losartan 1 No No 
C09CA03 Valsartan 2 No No 
C09CA07 Telmisartan 2 No No 
C09DA03 Valsartan/diuretic 1 No No 
C09DA07 Telmisartan/diuretic 1 No No 
Total  136 *   
* Note: This value is greater than (>) the total number of 79 who responded to Q3 
because more than 1 drug treatment, per general practitioner, was indicated in certain 
cases; all drug treatments were included in the analysis 
 
a) Adherence using the more conservative definition (second line treatment) 
 
Proportion adherent: p1 = 81/136 = 59.6% compared to ideal p2 = 135/136 = 
99.3% 
 
i) 95% confidence interval (95% CI) for p1 and p2 individually: 
95% CI for p1 = 59.6% = [51.31; 67.81%];  
95% CI for p2 = 99.3% = [97.83; 100.00%] 
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Since these two 95% CI’s do not overlap, there is a statistical significant 
difference between these 2 proportions: p2 is significantly larger than p1. 
 
ii) 95% CI for difference between p1 and p2: 
95% CI for p2-p1 = [31.33; 48.08%] 
 
Since 0 is not included in this 95% CI, one can conclude that there is a statistical 
significant difference between these 2 proportions: p2 is significantly larger than 
p1. 
 
iii) Hypothesis test: Z-statistic = 8.10; p-value = < 0.0001 
 
This hypothesis test concludes that there is a significant statistical difference 
between the 2 proportions compared, namely: 81/136 = 59.6% versus 135/136 = 
99.3%: p2 is significantly larger than p1 (a p-value < 0.05 is regarded as being 
statistically significant). 
 
b) Adherence using the less conservative definition (second line treatment) 
 
Proportion adherent: p1 = 96/136 = 70.6% compared to ideal p2 = 135/136 = 
99.3% 
 
i) 95% confidence interval (95% CI) for p1 and p2 individually: 
95% CI for p1 = 70.6 % = [62.93; 78.25%];  
95% CI for p2 = 99.3% = [97.83; 100.00%] 
 
Since these two 95% CI’s do not overlap, there is a statistical significant 
difference between these 2 proportions: p2 is significantly larger than p1. 
 
ii) 95% CI for difference between p1 and p2: 
95% CI for p2-p1 = [20.89; 36.47%] 
 
Since 0 is not included in this 95% CI, one can conclude that there is a statistical 
significant difference between these 2 proportions: p2 is significantly larger than 
p1. 
 
iii) Hypothesis test: Z-statistic = 6.61; p-value = < 0.0001 
 
This hypothesis test concludes that there is a significant statistical difference 
between the 2 proportions compared, namely: 96/136 = 70.6% versus 135/136 = 
99.3%: p2 is significantly larger than p1 (a p-value < 0.05 is regarded as being 
statistically significant). 
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With respect to the question ”What should the blood pressure of a hypertensive 
patient ideally drop to?”, 2 general practitioners chose not to complete this question. 
The data obtained from the remaining 77 general practitioners is represented in table 4 
below. 
 
Table 4: “What should the blood pressure of a hypertensive patient ideally drop to?” 
Descriptive statistics Systolic Blood Pressure 
(mmHg) 
Diastolic Blood Pressure 
(mmHg) 
n 77 77 
Mean 130.25 83.27 
Median 130.00 83.00 
Standard Deviation 8.99 5.04 
Minimum 100.00 70.00 
Maximum 145.00 90.00 
 
 
Sixty (60) (78%) general practitioners responded that they have heard of the SAHS 
guidelines; of those 60 only 21 (35% of those who have heard and 27% of the total) 
admitted to having a hard copy of these guidelines. Whereas when these 60 were 
asked if they followed the SAHS guidelines, 30 (50% of those who have heard and 
39% of the total) said that they did. 
 
Figure 4a: Pie chart indicating physicians that have heard of 
the guidelines and physicians that have never heard of the 
guidelines, with a breakdown of physicians with and without 
hardcopies 
22%
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Never heard of Guidelines
Heard of Guidelines (hardcopy)
Heard of Guidelines (rest)
 
Figure 4b: Pie chart indicating physicians that have heard of 
the guidelines and physicians that have never heard of the 
guidelines, with a breakdown of physicians that do and do not 
adhere to the guidelines 
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39%
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Never heard of Guidelines
Heard of Guidelines (adhere)
Heard of Guidelines (rest)
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When asked why the general practitioners did not adhere to the guidelines the 
following responses were obtained. 
 
Table 5: “If NO, why not?” (Responses to this question included the following 
categories) 
Category: Number of responses in 
this category: 
Did not know about or did not have the guidelines 16 (41.0%) 
Preferred using the JNC guidelines 4 (10.3%) 
Preferred to treat each patient individually or as a unique individual 11 (28.2%) 
Had no specific reason 2 (5.1%) 
Preferred their own logic 1 (2.6%) 
Patients could afford it they preferred starting off (first-line) with the 
most effective treatment 1 (2.6%) 
No handy references available 3 (7.7%) 
Too many guidelines 1 (2.6%) 
Total: 39 
 
 
When asked if the general practitioners thought that the guidelines were in touch with 
reality (or practical and implementable), 42 (54.54%) general practitioners felt that 
the SAHS guidelines are in touch with reality. Some of the general practitioners 
responded unknown (see pie chart below).  
 
Figure 5: "Do you feel that the SAHS Guidelines for the 
treatment of hypertensive patients are in touch with reality?"
58%29%
13%
Yes
No
Unknown
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When asked why the general practitioners thought that the guidelines were not in 
touch with reality, the following responses were obtained. 
 
Table 6: “If not, why?” (Responses to this question included the following categories)  
Category: Number of responses in 
this category: 
Preferred not to start patients on a diuretic 1 (4.2%) 
Guidelines do not take different populations into account 4 (16.7%) 
Guidelines are not aggressive enough in treatment 4 (16.7%) 
Guidelines do not take all factors into consideration 4 (16.7%) 
Not effective for patients in an uncontrolled environment 1 (4.2%) 
Guidelines are geared towards an academic environment and not 
private practice  4 (16.7%) 
Guidelines do not take into consideration the side effects of the 
drugs 2 (8.3%) 
Guidelines are too time consuming 4 (16.7%) 
Total: 24 
 
 
The general practitioners were asked for suggestions on how to make the guidelines 
more useful. These are their suggestions.  
 
Table 7: “Can you make any suggestions to make the guidelines more practical and 
implementable?” (Responses to this question included the following categories) 
Category: Number of responses in 
this category: 
Guidelines should consider more modern drugs and not ignore 
them just because of cost 4 (16%) 
Guidelines should consider more drugs that prevent cardiac heart 
failure  1 (4%) 
More input from general practitioners should be obtained and not 
specialist general practitioners 3 (12%) 
Guidelines should consider factors such as compliance, cost, side-
effects 4 (16%) 
More emphasis should be placed on follow-up 1 (4%) 
Guidelines should be more in line with JNC VII 3 (12%) 
Medical aids and payment of drugs via medical aids should be 
considered in guidelines 3 (12%) 
More should be done to make the guidelines public and known 4 (16%) 
Guidelines should be distributed as handy pocket guides, desk 
pads, etc 2 (8%) 
Total: 25 
 
 
 
The table below indicates the drugs which the general practitioners estimated that they 
prescribed most frequently irrespective of whether for 1st or 2nd line therapy. As can 
be clearly seen from the histogram below, the general practitioners estimated that they 
most frequently prescribed the ACE inhibitor group (24.56%) with the next most 
frequent being the ACE inhibitor combinations (13.16%). These were closely 
followed by Calcium Channel Blockers (12.28%) and Beta-blocking agents in 
combination with diuretics (12.28%). If, however, the ACE inhibitors, whether in 
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combination or not, is collapsed into one group (37.72%), it is clear that these were 
the most popular drug class for uncontrolled hypertension by a margin. If the same is 
done for the other classes, it is clear that the Beta-blocking agents (22.81%) were the 
second most popular group of drugs.  
 
Table 8: “Give an estimate of what drug you most frequently prescribe for 
uncontrolled hypertension?” 
Drug treatment 
code 
Drug treatment name Number of 
observations (n) 
Percentage (%) 
C02A Antiadrenergic agents, centrally acting 0 0 
C02C Antiadrenergic agents, peripherally 
acting (Alpha-adrenoreceptor 
antagonists) 
1 0.88 
C03 Diuretics 10 8.77 
C07A Beta-blocking agents 12 10.53 
C07B Beta-blocking agents, combinations 14 12.28 
C08 Calcium-channel blockers 14 12.28 
C09A ACE inhibitors 28 24.56 
C09B ACE inhibitors, combinations 15 13.16 
C09C Angiotensin II antagonists 11 9.65 
C09D Angiotensin II antagonists, 
combinations 9 7.89 
 Total 114 100 
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Figure 6: "Give an estimate of what drug you most frequently 
prescribe for uncontrolled hypertension."
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When asked for any additional comments, the following responses were obtained.  
 
Table 9: “Additional comments” (Responses to this question included the following 
categories) 
Category: Number of responses in 
this category: 
The guidelines are pointless as treatment is now totally dictated by our 
medical aids 4 (16%) 
I need a copy of the SAHS Treatment Guidelines 3 (12%) 
I would like a copy of the results of this study 2 (8%) 
Important to remember that guidelines should only guide and not dictate 3 (12%) 
There are too many guidelines for doctors to adhere to 3 (12%) 
I find the guidelines positive and helpful 6 (24%) 
I find the guidelines a waste of my time 4 (16%) 
Total: 25 
 
 
In order to determine who was adhering to the guidelines as opposed to who thought 
they were adhering to the guidelines (with respect to first-line therapy), responses to 
Q2 were compared to responses to Q7. Q2 was coded as “yes” if the drug that the 
general practitioner prescribed was according to the guidelines using the less 
conservative approach.  
 
Table 10: Comparison of Q7 vs Q2: 
 
Q2/Q7 Yes No 
Yes 16 14 
No 14 31 
 
Missing: 2xNo (2 respondents had missing results for Q2) 
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In order to determine who was adhering to the guidelines as opposed to who thought 
they were adhering to the guidelines (with respect to second-line therapy), responses 
to Q3 were compared to responses to Q7. Q3 was coded as “yes” if the drug that the 
general practitioners prescribed was according to the guidelines using the less 
conservative approach.  
 
Table 11: Comparison of Q7 vs Q3: 
 
Q3/Q7 Yes No 
Yes 18 32 
No 11 14 
 
Missing: 1xYes, 1xNo (2 respondents had missing results for Q3) 
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3.2 Results of the Secondary Analysis: 
 
Table 12: Frequency of prescription of Hypertension drug classes in MediCross® 
Clinics  
Drug class (SAMF drug treatment code and grouping – see table 8) Number of 
observations 
(n) 
Percentage 
(%) 
Antiadrenergic agents, centrally acting 116 24.12 
Antiadrenergic agents, peripherally acting (alpha adrenoreceptor 
antagonists) 22 4.57 
Diuretics (including and excluding thiazides) 32 6.65 
Beta-blocking agents  140 29.11 
Beta-blocking agents, combinations 20 4.16 
Calcium-channel blockers  40 8.32 
ACE inhibitors  79 16.42 
ACE inhibitors, combinations  17 3.53 
Angiotensin II antagonists  10 2.08 
Angiotensin II antagonists, combinations  5 1.04 
Total 481 100.00 
 
The above table was only discussed descriptively and no formal comparisons were 
made. Data from the MediCross® database was grouped according to the SAMF drug 
class system, in the same classes as Table 8. 
 
According to the MediCross® database the most frequently described drugs appeared 
to be the Beta-blocking agents (29.11%), followed by the centrally acting 
Antiadrenergic agents (24.12%) and the ACE inhibitors. If the Beta-blocking agents 
and ACE inhibitors, whether in combination or not, are collapsed, this order stays the 
same with the Beta-blocking agents at 33.27% and the ACE inhibitors at 19.95%. 
This is not in line with the frequency of the most prescribed drugs from question 2 
and 3, which were ACE inhibitors (although ACE inhibitors were frequent in the 
MediCross® dataset at 19.95%). This also appears to be different from the drugs 
thought to be most frequently prescribed by general practitioners in question 12, 
which was also found to be the ACE inhibitors. 
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4. DISCUSSION 
 
4.1 Introduction 
 
The null hypothesis (Ho) for this research report was defined as: medical practitioners 
in South Africa follow the Southern African Hypertension Society Guideline in the 
prescription of hypertensive drug treatments for patients suffering from 
uncomplicated hypertension. 
 
The alternate hypothesis (Ha) was defined as: medical practitioners in South Africa do 
not follow the Southern African Hypertension Society Guideline in the prescription of 
hypertensive drug treatments for patients suffering from uncomplicated hypertension. 
 
The study shows that, even with a less conservative approach (of the definition of 
diuretics is used) to the Southern African Hypertension Society Guidelines, general 
medical practitioners from urban areas of South Africa do not follow the guidelines 
for the prescription of antihypertensive medication. Furthermore, it was also shown 
that the group of general practitioners that did not comply was substantially larger 
than the group who did comply. The statistical analyses that were performed, shows 
that there is a statistically significant difference between the two groups. The study 
also shows that although some general practitioners are under the impression that they 
are complying with the guidelines, they are in fact not. 
 
The secondary analysis showed that Beta-blocking agents are the most frequently 
prescribed drugs for the treatment of uncomplicated hypertension in MediCross® 
Clinics in South Africa; this was not in line with the findings of the primary analysis 
questionnaire on the most frequently prescribed medication for uncomplicated 
hypertension in South Africa, whether it be first or second line.   
 
With a response rate of 81 out of a possible 320, it was clear that this could only be 
regarded as a pilot study (25.3%). 79 general practitioners (97.5% of responders) 
indicated that they did treat patients with uncomplicated hypertension and 2 general 
practitioners (2.5% of responders) indicated that they did not treat patients with 
uncomplicated hypertension (Table 1) as they were radiologists with the MediCross® 
Group. In other words 100% of general practitioners did treat patients with 
uncomplicated hypertension, which could be expected.  
 
4.2 Discussion on Choice of MediCross® General Practitioners  
 
From the start, the questions arose; “would MediCross® general practitioners be 
representative of the general practitioner in South Africa?”, “can an assumption be 
made that MediCross® doctors are a nationally representative?”. Some would say that 
they are limited by corporate guidelines, strategies and costs of bulk buying in what 
they are allowed to prescribe. Others would argue that, although there might be 
limited truth to this, it does or should not impact on the general practitioners choice of 
therapeutic drug class since they have an ethical obligation to prescribe what is 
scientifically required. A further argument, could be that the capitation model of 
healthcare provision under which MediCross® operates, could influence the choices 
of drugs prescribed. To try and put all of these questions, arguments and possible 
assumptions into perspective, one has to take a closer look at the company. 
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MediCross® was formed in 1992.  Today it is a managed healthcare provider network 
of 49 Family and Dental Centres, and other healthcare service providers, located in 
most urban areas within each of the provinces of South Africa (Appendix VII) [33]. 
Nevertheless there is a greater representation in the Gauteng region with 23 of the 49 
being located in this area. With respect to the respondents in my study, they were 
distributed fairly evenly across the urban areas of South Africa. 
 
It has grown to a point where it now has more than 320 doctors and 150 dentists 
practising at its facilities and handles in excess of 275,000 patients a month. For the 
purposes of this study, there was only an attempt to contact the doctors [34].  
MediCross® is a Network Healthcare Holdings Limited Group Company, which was 
purchased in October 2002. Netcare® currently owns 80% of MediCross®, with the 
balance being held by NetPartner Investments [34]. A more indepth view of the 
company and its policies requires an in depth view of the company profile. In the 
interests of accuracy and to avoid possible misrepresentation (should I misinterpret a 
company policy in the translation into my own words) as to what this company stands 
for I chose to directly quote sections out of the Corporate Profile of MediCross®. As 
per University regulations these quotes have been identified by “ ” and are written in 
italics. Furthermore, these sections, as obtained from the MediCross® website, have 
been reproduced with the permission of MediCross® (see Appendix VI).  
A Corporate Profile of MediCross® informs us that “MediCross® is a managed 
healthcare provider network traditionally servicing the Fee-For-Service medical aid 
and private primary healthcare market. More recently MediCross® has expanded the 
parameters of its operation, utilising its expertise in the fields of Practise 
Management and Managed Healthcare. The MediCross® Family Medical and Dental 
Centres offers its patients the benefits of convenience, top quality healthcare and 
affordability. Strong emphasis is placed on personal attention and a holistic approach 
to family healthcare. MediCross® is dedicated to serving the needs of the entire 
family, and as such the medical facilities are designed to cater for patients of all ages- 
from infants through to the elderly.” [34] 
“With a current shareholding of 80% owned by Network Healthcare Holdings 
Limited (The Netcare® Group) and the remaining 20% being held by Netpartner 
Investments Limited, the MediCross® Healthcare Group has experienced substantial 
growth and penetration in both the fee-for-service and managed healthcare arenas. 
Established in 1992 and born out of the belief that accessible, effective healthcare 
should be available to everyone at a price they can afford and without compromising 
the quality of service or overall treatment outcome, MediCross® has cemented it's 
position as a formidable player in the primary healthcare provider market. This 
internationally accredited network affords the patient, funder and provider the 
opportunity of being exposed to internationally recognised standards of patient care, 
health and safety regulations, and facility management that guarantee the delivery of 
a superior healthcare product.” [34] 
For the purposes of this study, it has to be taken into account that the Netcare® Group 
(including MediCross®), derives a large proportion of its income from pharmacies 
and the sale of drugs. This immediately raises the question: “Is it possible that there 
are formularies which may limit the drug choice not only overall but also within 
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medical aid plans to which the patient belongs? How does this impact on the care 
given?” Thus the question of pharmacy ownership also needs to be addressed. These 
questions are addressed below.    
 “The 320 General Practitioners and 150 Dental Practitioners that currently practice 
within the existing MediCross® Family Medical and Dental Centres are not 
employed by MediCross®, but rather comply to a contractual relationship and 
therefore maintain their professional independence, autonomy and integrity. These 
practitioners are supported within the facilities by teams of Physiotherapists, 
Dieticians and Psychologists, with another 150 medical specialists consulting at the 
various Centres on a permanent or part-time basis.” [34] 
This is a very important fact for the purposes of this study and must be considered in 
further assumptions. 
 “The MediCross® system holds certain benefits for both patients as well as 
providers.  Patients are assured of quality medical care through practitioner 
credentialing and selection, as well as employing a variety of unique tools and 
controls to ensure the delivery of consistent quality outcomes and the maintenance of 
pre-determined practice and practitioner performance criteria. These include: 
• Comprehensive Practice Audits that measure and monitor every aspect of 
each MediCross® Family Medical and Dental Centre and individual 
practitioner.  
• An Independent Peer Review System, where each practitioner is regularly 
evaluated against set parameters and against his colleagues.  
• Access to Clinical guidelines based on internationally accepted treatment 
protocols  
• Disease Management Programmes.  
• A Scientific Medicine Formulary is continually updated and utilised to 
eliminate wastage and the unnecessary use of costly drugs without 
compromising standards. Compliance to the formulary is strictly monitored 
through the monthly practice audit.  
• Continued Professional Development or Continuing Medical Education that 
keeps the professionals in the MediCross® system abreast of the latest 
advancements in healthcare.” [34] 
Based upon the above bullet points, in particular the last one, it was my impression 
that the MediCross® general practitioners may be better informed than the average 
and hence the results may reveal the best case scenario. Based upon the poor 
responder rate, I am reluctant to conclude that the results of my pilot study actually 
reflect the best case scenario. 
“These mechanisms allow for appropriate evidence based medicine to be practised 
and cost-efficiency to be monitored.  The ability to control healthcare costs is 
reinforced by the fact that the prescription rate in the MediCross® system is at least 
20% less than that of other general practitioners nationally.” [34]  
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 “As well as providing healthcare services at industry negotiated fee-for-service tariff 
rates for the medical aid and private patient, MediCross® offer a range of unique, 
comprehensive managed healthcare plans on a capitated basis (a fixed monthly fee) 
to look after the patient's individual healthcare requirements. Managed Healthcare is 
a means of providing healthcare services within a defined network of service 
providers, who in turn assume the responsibility and therefore the risk of providing 
quality, cost-effective care, while ensuring that only appropriate services are 
delivered. Under this model, emphasis is placed on keeping the patient well, rather 
than treating episodes of illness. In this environment the primary healthcare 
practitioner is responsible for managing downstream utilisation of services and 
effectively becomes the custodian of the patient's healthcare funds.” [34] 
“Demand for more affordable healthcare has resulted in the MediCross® Managed 
Healthcare product range, which offers extensive access to primary care services in 
return for an affordable fixed monthly premium. These products are currently listed 
as Options with ten open medical schemes and another two in-house medical aid 
schemes. The final product may vary, but essentially, differing levels of cover give the 
patient access to general practitioners, conservative dentistry, medicines (Acute and 
Chronic), pathology and radiology. The affordability of these products is evidenced 
by the fact that patients, by choosing a MediCross® managed care product can save 
up to 40% on comparable medical scheme contributions, without limiting benefits.  
There are currently approximately 40 000 beneficiaries on the various MediCross® 
managed healthcare products.” [34] 
If you take the above direct quotes (hence in italics and “ ” as per University 
regulations) from the Corporate Profile of MediCross® into account and the fact that 
uncomplicated hypertension, although very prevalent, is generally not a complicated 
condition to treat, again it was felt that for the purposes and context of this study, it 
would be reasonably safe to make the assumption that doctors will be honest in 
answering the questionnaire and where educated and aware of the SAHS Guidelines, 
and would follow them within reason. This was obviously done in the context of the 
information provided about the company and the environment in which these doctors 
practise medicine. 
In support of this the mission and philosophy of the company is quoted as “One of 
MediCross®’ aims is to provide all South Africans with the opportunity to access 
outstanding private healthcare. While it supports the concept of a competitive private 
healthcare system, the rise in medical costs in South Africa has led to the need to find 
creative ways to provide effective and affordable healthcare. MediCross® has 
successfully managed these costs through its Managed Healthcare programmes, 
which have allowed costs and treatment to be carefully monitored and controlled. 
MediCross®’ Managed Healthcare system has allowed the company to control 
medical costs without having to in any way compromise on care.” 
Further claims from MediCross® on the competitive advantage that their products 
have include: “With the emphasis on containing costs within the South African private 
healthcare industry, it has become ever more important for provider networks and 
funders to consider Managed Healthcare as a viable alternative to reduce the cost of 
healthcare delivery. MediCross® supports the view that business principles should be 
applied in the management of healthcare, but not at the expense of quality.” [34] 
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“Managed Healthcare therefore requires a delivery system that can influence the 
utilisation of services and measure performance outcomes without compromising 
quality of care. Managed care is also a means of taking responsibility for managing 
and providing quality, cost effective care, and ensuring that only appropriate services 
are rendered to patients.” [34] 
“MediCross®’ Managed Healthcare Programmes are based on a fixed monthly fee to 
the practitioner that is paid per patient in advance in exchange for providing the 
necessary healthcare services.  The emphasis of the MediCross® Managed 
Healthcare programme is on preventative care, rather than on treating episodes of 
illness. Unlike the traditional fee-for-service system, the MediCross® Healthcare 
programmes reward the doctor for keeping his or her patient healthy and for 
providing the best possible care. The healthier the doctor is able to keep his patient, 
the less the patient will visit and the lower the cost incurred in treating illness.” [34] 
“MediCross® Managed Healthcare programmes have been jointly developed with 
the doctors practising in the MediCross® facilities and other healthcare providers. 
Therefore, rather than medical schemes determining the benefit structure as is 
traditionally the case, the doctor helps to determine the benefit structure and assumes 
some of the risk for the patient's wellbeing.” [34] 
If one takes a more in-depth look at the managed healthcare products that are offered, 
MediCross® has developed a number of different products that are based around the 
practitioner who plays a central role in the process. The MediCross® Managed 
Healthcare Programmes are backed by the MediCross® Practitioners Association and 
supported by the professionals in the MediCross® system. 
“MediCross® is a network of healthcare providers, not a medical scheme. The 
MediCross® Managed Healthcare Programme, however, provides the mechanism for 
a comprehensive healthcare solution. Together with a client medical scheme, the 
MediCross® options can offer a comprehensive primary healthcare benefit package 
that also includes cover for specialist care, hospitals and ancillary benefits.” [34] 
“MediCross® has developed different managed healthcare programmes (please see 
Managed Healthcare Products section) with incremental levels of benefits. There is 
an entry level product aimed at the emerging market and providing a basic healthcare 
cover that is aimed particularly at young individuals in the lower income category. An 
intermediate product offers comprehensive healthcare at a very affordable rate 
whereas the top of the range product offers benefits competing with current fee-for-
service schemes at the top end of the market. This means that there is an option to suit 
all individuals, as well as at the same time catering for requirements of small and 
large employer groups and the medical schemes themselves.” [34] 
Based upon the above direct quotes (hence in italics and “ ” as per University 
regulations) from the Corporate Profile of MediCross® it is unlikely that belonging to 
a MediCross® managed general practice would influence the general practitioners 
decision as to which drugs to prescribe. Indeed some general practitioners stated that 
their reason for not adhering to the guidelines was that they felt that their patients 
could afford newer more expensive drugs and that it would be unfair to provide them 
with anything less. If the general practitioners had been bound by costs and hence 
influenced by MediCross® such reasons for poor adherence to the guidelines would 
have been unlikely. 
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The final important question for discussion on this issue, as mentioned above, is the 
availability and ownership of pharmacies. A detailed services search for all 
MediCross® Clinics, showed that more than 80% of all the clinics in South Africa 
have a Pharmacross Pharmacy® situated in the same clinic facility. The Pharmacross 
Pharmacy® group is wholly owned by the Netcare® Group and this can clearly be a 
cause for concern when the results of this study are interpreted. Taking the limited 
information available, as discussed above, into account, the fact that treatment 
guidelines are designed with the on-site pharmacies in mind, cannot be excluded and 
should be considered when assuming that this population is nationally comparable. 
 
Thus, taking all of the above into account, it was felt that it would be acceptable, but 
not fool-proof, to assume that the choices and practices of these general practitioners 
would, within reason, not unduly be influenced by external influences and corporate 
guidelines, although the possibility cannot be excluded. Therefore within the scope 
and reason of this study, patients were not treated differently to any other general 
practitioner (or patient) in urban areas of South Africa. 
 
It may be criticized that MediCross® doctors are not necessarily representative of all 
doctors. Indeed, I have clarified throughout that these results reflect those of general 
practitioners in urban areas only. Although an attempt was made to ensure that there 
was graphical representation (the 49 MediCross® practices are distributed across all 
provinces), the 81 General practitioners who responded were primarily from all the 
urban areas including Pretoria, Johannesburg, Bloemfontein, Kimberley, Cape Town, 
Durban, Port Elizabeth.  
 
4.3 General Discussion of Results 
 
For the primary analysis, the responses to question 2 were compared with the 1st step 
of the step-wise treatment approach in the guidelines (Figure 1). According to the 
guidelines, as a first step, general practitioners should prescribe a ‘low dose of a long 
acting once daily drug’ and more specifically a ‘low dose thiazide diuretic – 12.5 to 
25 mg hydrochlorothiazide’ for uncomplicated hypertension. Analysis done with this 
criteria showed that only 1 or 0.8% of cases, were compliant with the guidelines when 
prescribing first line medication. Because this percentage was so low, a second 
analysis was performed using less ‘strict’ criteria, in other words allowing a wider 
range of drugs for the first line treatment of uncomplicated hypertension as 
acceptable. Drugs allowed into the analysis included all diuretics (see Table 2). 
Compliance was found to be much higher at 43 or 33.1% of cases for this analysis. 
Although no other literature could be found to support this, it possibly shows that 
general practitioners interpret the guidelines for first line treatment as thiazide like 
diuretics or diuretics alone. Another reason might be that general practitioners do not 
want to target treatment at a blood pressure threshold alone as this is inefficient, and 
that treatment is targeted much more accurately at a specified level of absolute 
cardiovascular risk [18].  
 
Taking the responses for first-line therapy into account, literature also suggests that 
the need for drug therapy in uncomplicated, mild hypertension should be based on the 
absolute risk of cardiovascular complications, estimated by considering age, sex, 
serum cholesterol level, diabetes mellitus status, and smoking habits, in addition to 
blood pressure. Doctors cannot estimate absolute risk accurately informally or 
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intuitively, and the next generation of guidelines should incorporate a simple but 
accurate method for estimating cardiovascular risk, similar to that in the New Zealand 
guidelines [18].   
 
Further analysis for purposes of the primary objective, compared the responses to 
question 3 with the 2nd step of the step-wise treatment approach in the guidelines 
(Figure 1). According to the guidelines, as a second step, general practitioners should 
ADD a low dose diuretic or one of the following: reserpine (<0.1 mg daily), beta-
blocker, ACE inhibitor, long acting Ca-channel blocker, or a fixed dose combination. 
Analysis performed according to this criteria showed that 81 or 59.6% of cases, were 
compliant with the guidelines when prescribing a second line drug treatment for 
uncomplicated hypertension. To be consistent with the analyses performed for 
question 2, a less ‘conservative’ analysis was performed again, allowing for more 
acceptable second line treatment drugs. These mainly included any diuretics (not only 
low-ceiling or low dose) and again this analysis yielded a better compliance with the 
guidelines of 96 or 70.6% of the cases. From these results, it almost seems as if more 
general practitioners interpret guidelines on prescribing diuretics [first line (thiazide) 
vs second line (plain)] in less detail, not considering the difference between the 
thiazide diuretic and the plain diuretics. Again no literature was found to support this. 
For the second line treatment, it should however be mentioned that the difference 
between the ‘detailed’/’conservative’ and ‘less detailed’/’less conservative’ approach 
is not very big (only 15 extra general practitioners were included in the larger 
compliance of the second analysis for second line treatment). As described in the 
results section, the results for question 2 compared to an ideal compliance, shows a 
statistically significant difference (for the ‘conservative’ as well as ‘less conservative’ 
approach). The same is true for the question 3 comparisons. It is thus clear that 
medical practitioners in South African urban areas do not comply with the SAHS 
guidelines. 
 
A study performed in Spain [19] has shown similarly, that although a significant 
reduction in blood pressure control and in a percentage of patients with inadequate BP 
control, recommendations of the sixth JNC are widely not adopted in clinical practice. 
More doctors were not prescribing recommended drugs [19]. The opposite however is 
true for academic settings; where a study in the US has shown that a high level of 
awareness of primary care faculty and residents to diagnose hypertension according to 
JNC VI guidelines, may reflect a greater compliance with, or reliance upon, national 
guidelines in an academic setting, compared with general practice [20]. 
 
Responses to question 8 of the questionnaire for this study provided some insight into 
possible reasons for general practitioners not complying with the guidelines. These 
were categorized into general categories (see table 5) and included the following:  
 
- Did not know about or have a copy of the guidelines. 
- Preferred using the JNC guidelines. 
- Preferred to use their own knowledge and intuition. 
- Preferred to treat each patient as an individual. 
- Preferred to treat patients who can afford it more aggressively early on. 
- Had no specific reason. 
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Responses to question 9 and 10 of the questionnaire for this study also provided 
some insight into why doctors might feel that the guidelines are not practical and ‘in 
touch with reality’. Fifty eight and a third percent (58.33%) of the doctors interviewed 
felt that the guidelines were practical, 12.5% were unsure and the remaining 29.17% 
felt that the guidelines were unpractical. This means that 41.76% were not convinced 
of the guidelines’ validity and implementability, which might be another explanation 
of the lack of compliance as found in this study. Reasons why doctors felt that the 
guidelines were not practical were listed in table 6 and included issues like pricing, 
medical insurance (aid), side-effects, differences in risk profiles and assessment 
thereof and the aggressiveness of treatment. On this same topic, responses to question 
11 produced some suggestions as to how doctors felt guidelines could be made more 
practical and these also pointed towards perceptions of why guidelines might be 
lacking. As can be expected, the responses were mostly related to those given in 
question 10. 
 
The responses to questions 8, 9, 10 and 11 make it fairly clear why doctors in this 
population do not comply with the guidelines. They feel that the guidelines are not 
practically implementable and they feel that the guidelines limit their initiative. An 
important factor, that was mentioned by many of the doctors and that needs more 
exploration, is the role that medical insurance (aid) plays in influencing what drugs 
the doctors prescribe. Many doctors felt that guidelines are ‘useless’ purely because 
pricing and medical insurance dictates treatment more than any other factor. 
 
Other studies have shown similar factors influencing doctors’ decisions on drug 
treatment of uncomplicated hypertension [17, 21]. Determining factors mentioned, 
that support the findings and responses above, includes patient preferences, 
socioeconomic factors and differences in risk of CVD complications [21].  
    
Patient values and preferences need to be an integral part of evidence-based 
decisions. The clinician cannot presume full responsibility for determining what is in 
the best interest of their patients. Instead, a shared decision-making approach is 
advocated, in which patients are the experts at judging their own values. For this 
approach to work, patients first need to be properly informed about their condition, 
the treatment options, and the outcomes of treatments, including possible 
complications. Side-effects that compromise functional capacity are of particular 
relevance. Trade-offs between short-term and long-term outcomes should be 
articulated. This strategy seems to work [21]. A recent trial showed that use of 
cardiovascular risk chart in patient education was associated with better BP control 
[22]. Other research has suggested improved medication adherence when patients are 
involved in decisions regarding treatment choices [23]. The value of various decision 
aids for patients has been reviewed through the Cochrane Collaboration [24].    
 
Drug costs is a major consideration for hypertensive subjects. The choice of an 
antihypertensive drug should be based on its value to the patient and society. There 
are marked differences in cost between classes of antihypertensive drugs and in some 
instances even between agents within a class. Guidelines ought to incorporate the role 
of cost and socioeconomic factors in making treatment decisions. If two 
antihypertensive agents offer a similar reduction in risk of cardiovascular 
complications, but they clearly differ in cost, the less expensive agent is more cost-
effective and should be recommended. The unnecessary and unwarranted use of 
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expensive agents precludes the use of these resources for other effective preventative 
efforts. Generic formulations of all antihypertensive medications should be 
recommended when they are available. Guidelines ought to acknowledge the role of 
socioeconomic factors in making treatment decisions [21].  
 
This supports the fact that many general practitioners prefer to prescribe a newer 
generation drug for first-line treatment and since this study was carried out at private 
practices and most of the patients treated by these general practitioners have some 
kind of medical insurance, cost would not be an influencing factor, as diuretics are 
generally less expensive drugs. In fact some general practitioners indicated (see Table 
5 above) that they do not follow the guidelines because they feel that their patients 
can afford the so-called newer and more expensive drugs and that it would be unfair 
to provide anything less.  
 
Cardiovascular complications of hypertension differ in different populations. For 
example, stroke incidence is higher than acute MI in Asian populations, and in elderly 
whites. Important differences exist between drug classes in their effect on the risks of 
stroke, acute MI, heart failure, and renal complications [25]. Thus, population 
differences in types of CVD complications are other factors to consider both in the 
assessment of risk, and in the selection of drugs.  
 
However one looks at it, there are many factors that can influence a general 
practitioner’s choice to follow the guidelines or not and these should be subjected to 
further investigation. Indeed, as my pilot study indicates further research into these 
issues is certainly required.   
 
Question 7 asked general practitioners if they follow the SAHS Hypertension 
Treatment Guidelines when prescribing drug treatments for hypertensive patients. 
Analysis of the responses showed that 30 or 38.96% of general practitioners 
responded positively, in other words they believe that they are being compliant with 
the guidelines. Forty seven (47) or 61.04% responded negatively and believe that they 
are not complying with the guidelines. To confirm if general practitioners might be 
under the wrong impression regarding their compliance, for example they might think 
they are compliant and they are actually not or vice versa, a comparison was 
performed between questions 7 and 2 (Table 10) and between questions 3 and 7 
(Table 11). 
 
Of the 30 general practitioners who believed that they were compliant, only 16 were 
actually compliant with the prescription of first line drug treatment (Table 10). This 
means that 14 or 47.7% of the general practitioners were not compliant even though 
they thought they were. This alone, suggests strongly that more investigation is 
needed into general practitioner education on the use of the guidelines for first line 
drug therapy. 
 
Of the 30 general practitioners who believed that they were compliant, only 18 were 
actually compliant with the prescription of second line drug treatment (Table 11). 
This means that 11 (two general practitioners did not answer question 3) or 37.9% of 
the general practitioners were not compliant, even though they thought they were. 
Again, this strongly suggests that education in the application of the guidelines for 
second line therapy is most likely lacking.  
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Of the 45 general practitioners who believed that they were not compliant, only 31 
were actually not compliant with the prescription of first line therapy (Table 10). This 
means that 14 or 31.1% of the general practitioners were compliant without their 
knowledge and again can be is assumed that they were not adequately educated in the 
use of the guidelines.  
 
Of the 46 general practitioners who believed that they were not compliant, only 14 
were actually not compliant with the prescription of second line therapy (Table 11). 
This means that 32 (two general practitioners did not answer question 3) or 69.6% 
were compliant with guidelines without their knowledge and again it can be assumed 
that they were not adequately educated in the use of the guidelines. 
 
Question 4 assessed what the general view on the ideal blood pressure is. Results are 
reported in Table 4 with the median SBP being 130 mmHg and the median DBP 
being 83 mmHg. The average suggested ideal SBP was 130.25 mmHg with a standard 
deviation of 8.99 mmHg and the average suggested ideal DBP was 83.27 mmHg with 
a standard deviation of 5.04 mmHg. The minimum suggested SBP was 100 mmHg 
and the maximum suggested SBP was 145 mmHg. The minimum suggested DBP was 
70 mmHg while the maximum suggested DBP was 90 mmHg. 
 
The above SBP and DBP results correlate well with the international perception, but 
literature shows that even in international circles there are still major differences in 
opinion of what an ideal BP should be [18]. The BP level at which antihypertensive 
therapy should be introduced and the goal of intervention has not been adequately 
addressed in clinical trials. The form and intensity of treatment, and the level to be 
sought, should be influenced by the magnitude of risk as well as other individual 
clinical and non-clinical factors. Grading of recommendations and evidence for 
thresholds and targets should also be included [21].     
 
Question 5 asked general practitioners if they had ever heard of the SAHS 
Hypertension Treatment Guidelines. Results are reported in Figure 4a and 4b. It was 
found that 60 or 78% of the general practitioners had heard of the guidelines and that 
17 or 22% had not heard of the guidelines. As a follow-up to question 5, question 6 
asked general practitioners if they had a hard copy of the SAHS Hypertension 
Treatment Guidelines. 21 General practitioners (27%) indicated that they had copies 
of the guidelines and 56 (73%) indicated that they did not have a hard copy. The 
results of the responses to this question should serve as a indication to the SAHS if 
they are doing enough to make general practitioners aware of these guidelines and 
their availability.   
 
Question 12 asked general practitioners to provide an estimate of what drugs they 
most frequently prescribe for uncontrolled hypertension in the hope that this could be 
compared to the results of the secondary analysis. The most frequently prescribed 
drug (37.72% of total), as reported by the general practitioners on the questionnaire 
(Table 8), proved to be the ACE inhibitors. More detail on the comparison of this 
result with that of the secondary analysis will be discussed below.    
 
Lastly, question 13 provided general practitioners the opportunity to note any 
additional comments. It was clear from most comments that the guidelines should 
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only be viewed as guidelines that provide direction and that they are not law. Further 
positive comments included requests for the guidelines and requests for results of this 
research project. One comment that was made stated “Big difference between 
academic and private practice medication. Patients do not allow so much “cheap-
changes” in private practice – they want effective and immediate treatment with a low 
side effect profile”. Perhaps this summarises and supports reasons for the lack of 
compliance, as previously mentioned. 
 
Data from the MediCross® database showed, as part of the secondary analysis, that 
Beta-blocking agents (selective, non-selective, plain and in combination) have been 
the most commonly prescribed medication for the treatment of uncomplicated 
hypertension over the last 2 – 3 years (33.27%) (See Table 12 for more detail). This is 
not the same as the results yielded by question 12 (ACE inhibitors). More 
investigation will be needed to assess possible reasons for the difference in results. 
 
Literature does however support the results of the primary analysis and it has been 
found that ACE inhibitors are the most frequently prescribed antihypertensives in 
first-world health settings, especially in patients with congestive heart failure [26]. 
This also confirms that the results of this study will probably be more relevant to the 
private health sector of urban areas of South Africa as this sector compares well to 
first world healthcare sectors.  
 
Having said all of this, it should be noted that the data obtained from MediCross® is 
questionable. The number of hypertensives treated is low. Another concern is that 
there were only 4 prescriptions in 3 years for thiazide diuretics alone. Then there are 
some curious combinations of drugs and drug-classes. The secondary analysis was 
done, in part, to compare and assess the validity of the results of the primary analysis. 
Although at the outset on embarking on this study, I was of the opinion that the 
database consisted of prescriptions, it is not clear if the drug names provided were 
actually those supplied rather than prescribed. Indeed it is possible that the 
prescriptions were changed and different drugs dispensed as the results of the general 
practitioners recall (Table 8) were not comparable to those of the analysis of the data 
base (Table 12). It should be stressed again that this database was received on face 
value, assuming a reasonable degree of accuracy, however, retrospectively it became 
clear during the analysis that the accuracy is questionable. This may be due to a 
number of reasons of which improper database administration and management is the 
most likely cause. Nevertheless, the concerns about the accuracy of this database 
certainly cast some doubt on the results of the secondary analysis. 
 
 
4.4 Survey Methods 
 
For the purposes of this study, a questionnaire was utilized as the primary data 
collection tool. Initially, telephonic interviews were planned and they were executed 
for the first 5 participants. Of these, 1 candidate was not interested to participate and 4 
did participate. It was clear from these 5 candidates that telephonic interviews were 
going to be very time consuming as the general practitioners were occupied with 
patient consultations and did not want to make time available over the phone. When 
general practitioners were available to take telephone calls, they were extremely 
 - 43 - 
rushed and the questionnaire had to be administered in a hurried fashion. It became 
clear that the time constraints on general practitioners were going to make proper 
interviewing very difficult. Furthermore, it would take a number of phone calls from 
the investigator to be able to talk to one general practitioner. With a target population 
of 320 doctors and no formal funding for the study, it was decided that a telephonic 
interviewing process would take too much time and would be too costly, even though 
if done, might have yielded a better response rate. Although a previous study has used 
focus group discussions and in-depth interviews [17], these can only be done in small 
select groups who are unlikely to representative of all general practitioners. 
Furthermore, practicalities would have resulted in these interviews or discussion 
groups having been conducted in possibly only one region of South Africa and hence 
the results would not have been nationally representative. 
 
In order to approach the general practitioners a covering letter, providing a brief 
standardized outline of the study was generated. Wording in the cover letter was as 
follows:  
 
(“Please see attached questionnaire. I am a M.Sc.(Med) student from the WITS 
medical school and as you can see from the questionnaire, I am conducting a 
research project for academic purposes. I have collaborated with the MediCross® 
head-office and Mr. P. Dorfling has given me written permission to contact you in this 
regard. I will try to determine (with your help) how relevant and practical the SAHS 
guidelines are and if general practitioners do actually follow them when prescribing 
treatment. Please note that participation is voluntary and anonymous and consists of 
yourself answering the attached questionnaire. It should not take you more than a few 
minutes. Please use tradenames as far as possible. 
 
Your particpation is greatly appreciated and will determine more accurate results 
(the more participants, the more accurate my statistical conclusions). 
 
Please fax the answered questionnaire to me at (011) 319 8705 at your earliest 
convenience. 
 
It was decided to fax the cover letter and questionnaire to the remaining 315 doctors. 
It was decided not to change the questionnaire for the purpose of standardization. 
 
All questionnaires that were received (faxed back), were allocated with an ID number 
and filed as source documentation. These are available for monitoring purposes and 
will be archived for at least one year. 
 
A questionnaire can be defined as a tool designed to elicit and record, or guide the 
elicitation and recording of, recalled exposures from subjects of a study. It contains 
questions to be put to the subject, and may also include answers to those questions 
from which the subject must choose those which are appropriate to him or her. The 
objectives of questionnaire design are:  
 
• to obtain measurements of exposure variables essential to the objectives of the 
study 
• to minimize error in these measurements 
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• to create an instrument which is easy for the interviewer and subject to use, 
and for the investigator to process, and analyse. 
 
The objectives are potentially in conflict, and any questionnaire usually represents a 
compromise among them. For example, it may be necessary to trade off some ease in 
processing and analysis against ease in completion by the interviewer or the subject. 
Similarly, the addition of some questions essential to the objectives of the study, for 
example questions about sexual behaviour in a study of the aetiology of cancer of the 
cervix, may make a questionnaire more difficult for an interviewer to administer and 
more threatening to the respondent. Judgement must be exercised in making decisions 
about the content and structure of questionnaires. Where compromise is necessary, the 
designer should favour decisions that maximize the usefulness of the questionnaire to 
the objectives of the study and minimize error in measurement [27]. 
 
In this study there was a compromise on maximizing the usefulness of the 
questionnaire to the objectives of the study and as a consequence error in 
measurement was not considered very carefully. 
 
The content of a questionnaire is generally designed to investigate the minimum 
amount of an individual’s total experience that will provide sufficient information 
concerning the problem under study [27]. Just as the objectives of the study determine 
the variables to be measured as a whole, they also determine the specific items to be 
covered in the questionnaire. If a question does not contribute to the achievement of 
the objectives, it has no place in the questionnaire. 
 
The topics to be covered in a questionnaire and the detail in which they are covered 
are limited first and foremost by the length of time that subjects are willing to spend 
on the questioning process. While there are inevitable exceptions, it may be taken as a 
general rule that the maximum time that can be spent administering a questionnaire by 
face-to-face interview is 1-2 hours and, by telephone, 40 minutes to 1 hour. Self-
administered questionnaires are at an added disadvantage in that the subject can gain 
an impression of the size of the response task before deciding whether to embark on 
it. Response rates among the general public appear not to be appreciably depressed by 
questionnaires of up to a maximum of 12 pages in length [28]. In other words the 
shorter the questionnaire the better. 
 
As mentioned above, there is often a conflict between collecting information 
considered to be necessary to the objectives of the study, keeping the questionnaire an 
acceptable length, and minimizing other aspects of respondent burden. In resolving 
this conflict, it is important not only to collect the minimum amount of information 
necessary to the objectives of the study, but also to ensure that questionnaire length 
and respondent burden are kept to levels that do not threaten participation by subjects 
or cause material increase in error. Although respondent burden was low in the 
questionnaire in this study, it can be said that the fact that the questions were perhaps 
not very clearly defined and detailed, could have contributed to a high respondent 
burden. The increased burden on the respondent could have contributed to several 
consequences: 
 
• risk of partial non-completion increased as this was a self administered 
questionnaire 
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• reduction of the quality of data obtained 
• threatened response rate (which was clearly visible in this study) 
• an alienation to survey research and cooperation due to poorly designed 
questionnaires (past and future) [29] 
 
Questions used in the questionnaire can generally be classified as either ‘open-ended’ 
or ‘closed-ended’. Open-ended questions are questions to which no answers are 
provided by the investigator. Only the question is asked, and the respondent’s answer 
is recorded verbatim e.g. questions 2, 3, 4, 8, 10, 11, 12, 13 for the questionnaire used 
in this study. In an interview, extensive probing may be used to ensure that all 
relevant aspects of the topic are covered by the answer. Closed-ended questions are 
questions for which the range of possible answers is specified by the investigator and 
the respondent is asked to make a choice from among the answers provided. 
 
Open-ended questions should be used for the eliciting and recording of simple facts to 
which there are a large number of answers – for example, age, occupation, country of 
birth, number of cigarettes smoked in a day, amount of alcohol drunk in a particular 
period of time, etc. The use of closed-ended questions for these topics leads to loss of 
information and, when asking about a socially undesirable behaviour, a greater degree 
of error. An additional advantage of open-ended questions is that the amount of a 
particular behaviour reported in closed categories may be influenced by the cut-off 
values chosen for the categories. It appears that the categories offered are seen as 
normative by the respondents and their responses are influenced away from the 
extremes, particularly if one or other extreme is viewed as socially undesirable. When 
the likely answer to an open-ended question is neither simple nor factual, the use of 
such a question increases the burden on both respondent and interviewer and produces 
answers that are difficult both to code and to analyse. This can clearly be seen from 
questions 8, 10, 11, 12, 13 in the questionnaire used here. 
 
The alternative answers offered in a closed-ended question should be simple and 
brief, and mutually exclusive if only one is to be selected. If more than one response 
could be selected, it may be best to seek explicit ‘yes/no’ responses for each of the 
categories. If the response categories provided are not exhaustive of all possible 
responses, a final open category (e.g. ‘Other. Please give details…’) should be given. 
A ‘Don’t know’ option may also be offered if the possibility exists that some subjects 
will truly not know the answer. It has been shown however, that the exclusion of the 
‘Don’t know’ option gave an appreciably higher proportion of usable responses for 
many items without adversely affecting response rate or intramethod reliability [30]. 
For these reasons the inclusion of a ‘sometimes’ option was avoided. It was felt that 
there would be a tendency for most responders to choice this option in favour of either 
definitive option (yes or no), especially if they did not know as to which definitive 
answer was more desirable.   
 
Another important factor to consider in questionnaire design is question wording. 
There are two important issues to be considered in question wording: 
 
• How does one arrive at a suitable wording in the first place? 
• Are small changes in wording likely to lead to differences in response? 
Table 13 [31] gives a list of questions that should be asked about the wording of each 
question in a questionnaire. 
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Table 13: Questions that should be asked about the wording of each question in a 
questionnaire [31]. 
 
• Will the words be uniformly understood by the subject population? 
• Does it contain abbreviations, unconventional phrases, or jargon? 
• Is it vague? 
• Is it too precise? 
• Is it biased? 
• Is it threatening? 
• Does it contain more than one concept? 
• Does it contain a double negative? 
• Are the answers mutually exclusive? 
• Does it assume too much about the respondent’s behaviour? 
• Is an unambiguous time reference provided? 
• Is the question cryptic? 
 
The words used in a questionnaire should be the usual ‘working tools’ of the 
respondents. They should be neither too difficult nor too simple. Difficult words may 
not be understood, and simple words (where better but more difficult words could 
have been used) may appear condescending, may not convey the right meaning, and 
may needlessly lengthen the questionnaire. Where doubt exists, however, there is a 
virtue in simplicity [32]. Abbreviations, unconventional phrases, and jargon present 
the same problems as difficult words; they may not be understood or, perhaps worse, 
they may be misunderstood. In this questionnaire one abbreviation was used (SAHS – 
“Southern African Hypertension Society”) in questions 5, 6, 7 9. However unlikely it 
is that this abbreviation was misunderstood in the context of the questionnaire and 
taking into consideration that the respondents were well educated, it cannot be ruled 
out that this abbreviation was perhaps misinterpreted or not understood at all.  
 
Questions may contain vague words – words that vary substantially in their meaning 
among different people. ‘Usually’, ‘normally’, and ‘regularly’ are three commonly 
used vague descriptors of frequency. In many circumstances they can be replaced by 
more precise quantifiers. Furthermore, while precision is desirable, particularly when 
estimating amount or duration, respondent burden may be increased unduly if too 
much precision is requested.  
 
Biased questions are questions that suggest to the respondent that a particular answer 
is preferred from among all possible answers. ‘Leading’ questions are well known and 
should be easily avoided. In this light, it can be argued that questions 9-11 of the 
questionnaire used in this study can be viewed as biased questions. The same can be 
said about questions 6 and 7 and the fact that they might be viewed as threatening 
questions. 
 
Questions in this questionnaire were evaluated and found not to include any double 
negatives, multiple concepts in one question, mutually exclusive answers, 
assumptions about the respondents, unambiguous time references, or cryptic 
questions. 
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Pre-testing is an essential part of the development of all questionnaires, regardless of 
whether or not they have been substantially based on previous questionnaires. The 
objectives of pre-testing are to identify questions that are poorly understood, 
ambiguous, or evoke hostile or other undesirable responses. Some of the questions 
that a pre-test should answer are [31]: 
 
• Are all the words understood? 
• Are the questions interpreted similarly by all respondents? 
• Does each closed-ended question have an answer that applies to each 
respondent? 
• Are some questions not answered? 
• Do some questions elicit uninterpretable answers? 
 
The steps that should be followed in pre-testing a questionnaire are summarized in 
Table 14 [28].  
 
Table 14: Steps in the pre-testing and final development of a questionnaire [28]. 
 
1. Obtain peer evaluation of the draft questionnaire. 
2. Test the revised questionnaire on a sample of convenience (e.g. yourself, 
relatives, friends and colleagues). 
3. Prepare instructions for use of the revised questionnaire and train interviewers 
for a pilot test. Problems requiring revision of the questionnaire may be 
uncovered in this process. 
4. Pre-test the questionnaire on a sample (20-50) of respondents representative of 
the population from which your subjects will be drawn. 
5. Obtain comments of interviewers and subjects, preferably in writing. 
6. Revise questions that cause difficulty. 
7. Pre-test and revise again. 
8. Prepare revised instructions and train interviewers for implementation of the 
study. Revise questionnaire if this process uncovers more problems. 
9. Monitor performance of the questionnaire during the early phase of the study 
and be willing to stop, revise, and pre-test again if necessary. 
 
After completion of administration, each question should be read back with its answer 
and the respondent asked how he or she arrived at the answer. Probing may be 
necessary to clarify the answer to this question. A serious of questions should then be 
asked about how each concept in the original question was understood. A pre-test 
interview can be taped and listened to by the investigator (if not administered by 
himself) [33]. Due to time constraints and a lack of understanding of the necessity of 
pre-testing, the questionnaire in this study was not pre-tested. This may indeed have 
impacted on the validity of the questionnaire administered (and hence the results 
obtained) in this study. 
 
Presentation of the questionnaire in printed form is important, especially when it is to 
be self-administered both for ease of use and to give it an authoritative appearance 
that will encourage response. The first page should include the title of the study, the 
name of the organization conducting it, and the date. In addition, a graphic illustration 
may make a self-administered questionnaire more attractive to its target population. 
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Pages and questions should be numbered consecutively, and subsections of questions 
should be indented and identified with letters rather than numbers. As far as possible, 
questions should not extend over more than one page. Following this rule will 
generally increase the amount of space between questions and it is indeed important 
that the questionnaire not be too congested. 
 
In a self-administered questionnaire the last page should provide space and a specific 
invitation for any comments that the subject may wish to make. Interviewer-
administered questionnaires should provide for the entry of the starting and finishing 
times and the interviewer’s comments. 
 
4.5 Study Limitations 
Given the discussions above, I should state that there are indeed three limitations to 
my pilot study. Firstly, the MediCross® general practitioners may not necessarily be 
representative of all general practitioners in urban areas of South Africa. Indeed the 
general practitioners who responded tended to be located primarily in the bigger city 
(urban) regions. 
 
Secondly, the questionnaire was not piloted which may have led to invalid 
interpretations and hence responses. Although a simple 13 question self-administered 
approach was used to minimize respondent burden in the aim of maximizing 
responder rate, the responder rate was indeed very poor. The poor responder rate itself 
is a further limitation in that these responders may not be representative of the whole 
group. Further limitations pertaining to possible leading questions, threatening 
questions and the use of many open-ended questions has also been discussed.    
 
Thirdly, the accuracy of the MediCross® database has been questioned, hence casting 
some doubt on the results of the secondary objective. 
 
Given these limitations in mind, I would urge that further, more thorough 
investigations be performed. Such studies would need to be extensive and hence 
would we time and labour intensive. I would recommend that in-depth interviews and 
focus group discussions be conducted in all regions of South Africa. Studies should be 
conducted separately to canvas opinions in urban versus rural general practitioners, as 
it is possible that opinions may differ. It is also important that in these studies the 
general practitioners should be representative of all races and both genders.  
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5. CONCLUSIONS 
 
In my pilot study, the primary analysis showed that, even with a less conservative 
approach (with respect to the definition of diuretics) to the Southern African 
Hypertension Society Guidelines, general medical practitioners in urban areas of 
South Africa do not follow appear the guidelines for the prescription of 
antihypertensive medication. 
 
The secondary analysis showed that Beta-blocking agents are the most frequently 
prescribed drugs for the treatment of uncomplicated hypertension in MediCross® 
Clinics in South Africa; this was not in line with the findings of the primary analysis 
questionnaire on the most frequently prescribed medication for uncomplicated 
hypertension in South Africa, whether it be first or second line.   
 
The results of my pilot study suggest that the practitioner’s perception is that the 
definition of hypertension and its management is contentious. Furthermore, the 
treatment of hypertension seems to vary widely. It is the concern of the practitioner’s 
that there is no optimal BP or multifactor CVD risk level at which BP-lowering 
treatment should be initiated in all situations. Nor is there a single treatment regimen 
appropriate for all populations and every patient. It is clear from the general 
practitioners responses that, clinical guidelines for the management of hypertension 
should accurately reflect that uncertainty and variation if they are going to take these 
guidelines seriously and comply with them. Furthermore it is of concern that although 
at least 2/3 of practitioner’s that responded had heard of the Southern African 
Hypertension Society Guideline, less than one third had a hard copy of the guidelines.  
 
There is no doubt that the production of clinical guidelines requires much effort, 
resources, and commitment of time on the part of many. Their publication is the 
culmination of both scientific and social processes intended to include all relevant 
evidence as well as all appropriate stakeholders. Their formulation needs judgment, 
compromise, and simplification to achieve consensus. However, based on the 
responses from the practitioner’s, the inclusion of diverse views in accompanying 
editorial or discussion segments may help to put guidelines into perspective and make 
them more popular with general practitioners. 
 
As guidelines assemble the available data from basic biomedical science, 
epidemiology, and clinical science in an accessible form from which general 
practitioners and patients can make reasoned decisions for individual cases, they are 
indeed invaluable. However, the results of my pilot study suggest that the current 
guidelines are neither widely accepted, nor effectively implemented. Further studies 
are required to address these questions in more detail and across all general 
practitioners in South Africa. 
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